Drug intelligence / Profile preview

AI01

Development stage: Preclinical
Lead developer: Amprologix
Modality: Peptides
Administration: Topical, Intranasal, Inhalation, Intravenous

Overview

AI01 is a preclinical-stage, AI-designed antimicrobial peptide being developed by Amprologix for the treatment of *Clostridioides difficile* infection (CDI). Developed using artificial intelligence to optimize potency and selectivity, AI01 belongs to a class of engineered antimicrobial agents intended to treat bacterial infections while preserving the host's natural gut microbiome. The program is currently in the preclinical phase of development and represents a novel approach to addressing antibiotic-resistant pathogens through computational design.

Beyond the preview

Go deeper on AI01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AI01.

Explore the full profile